Vaso Occlusive Crisis Market Report and Forecast 2025-2034
Description
The vaso occlusive crisis market was valued at USD 4.81 Billion in 2024, driven by the increasing prevalence of sickle cell disease across the 8 major markets. The market is expected to grow at a CAGR of 14.74% during the forecast period of 2025-2034, with the values likely to reach USD 19.02 Billion by 2034.
Vaso Occlusive Crisis Market Overview
Vaso occlusive crisis is considered the most common clinical manifestation of sickle cell disease. The frequency of crisis is reported to be extremely variable, with some individuals experiencing up to 6 or more episodes in a year. The increasing prevalence of sickle cell disease and the growing patient awareness are expected to augment the market demand for effective treatments. The market is also affected by the rising advancements in gene therapies and increased R&D expenditure by biotechnology and pharmaceutical companies. Moreover, the growth in clinical trial activity and robust regulatory support are some of the factors projected to positively influence the market dynamics in the coming years.
Vaso Occlusive Crisis Market Growth Drivers
Increasing Prevalence of Sickle Cell Disease Drives Market Growth
In the United States, sickle cell disease is reported to affect around 100,000 individuals, comprising over 90% non-Hispanic Black or African American and around 3-9% of Hispanics or Latinos. Further, the disease is highly prevalent in India, particularly among the tribal population. Since vaso occlusive crisis is one of the most common clinical manifestations of sickle cell disease, the rise in the number of such individuals is poised to boost the market growth in the forecast period. Additionally, this rising disease burden is anticipated to propel new drug development efforts for better management of vaso occlusive crisis.
Vaso Occlusive Crisis Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Robust Regulatory Support to Affect the Market Landscape Significantly
In December 2023, two cell-based gene therapies Casgevy and Lyfgenia, developed by Vertex Pharmaceuticals Inc. and Bluebird Bio Inc., respectively, were approved by the U.S. Food and Drug Administration for the treatment of sickle cell disease in patients aged 12 years and above experiencing vaso-occlusive crises. The rise in such approvals by the health authorities is expected to fuel the market growth in the coming years.
Shift Toward Disease-Modifying Therapies Poised to Augment Vaso Occlusive Crisis Market Demand
The market is witnessing a shift towards the development of therapies that target the root cause of sickle cell disease rather than focusing on addressing symptoms that arise during vaso occlusive crisis. Pharmaceutical companies are exploring new therapies that have the ability to alter red blood physiology in order to reduce the frequency of vaso occlusive crisis events and improve overall patient outcomes.
Growth in Clinical Trials to Elevate the Vaso Occlusive Crisis Market Value
Increased clinical trial activity to examine the effectiveness and safety of new treatments for managing vaso occlusive crisis is a major market trend. For instance, Novartis Pharmaceuticals is conducting a Phase II clinical trial to establish and confirm appropriate dosing as well as to examine the safety of its drug crizanlizumab in pediatric patients (aged between 6 months and 18 years) suffering from sickle cell disease with vaso occlusive crisis. The surge in such clinical studies is anticipated to elevate the market value in the forecast period.
Increased Screening Programs to Boost Vaso Occlusive Crisis Market Size
One of the significant market trends is the increase in the number of comprehensive screening programs in high-prevalence regions in order to improve the management of sickle cell anemia and vaso occlusive crisis in the affected patients. National Sickle Cell Anaemia Elimination Mission is one such program launched by the government of India in July 2023, under which 3.37 crore people were screened. Such large-scale screening initiatives are set to augment the market growth in the near future.
Vaso Occlusive Crisis Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type:
Market Segmentation Based on Treatment Type is Likely to Witness Substantial Growth
The market breakup by treatment type includes gene therapy and supportive care. The gene therapy segment is poised to dominate the market share owing to the rising advancements in CRISPR technology and other gene editing methods. Further, there is an increase in the number of clinical trials aimed at correcting the defective hemoglobin gene, which is likely to fuel the growth of this segment in the coming years.
Vaso Occlusive Crisis Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States holds a substantial market share which can be attributed to the presence of key market players and the high clinical activity in the region. The market also benefits from the increasing research funding for gene therapies and the growing demand for advanced therapies for vaso occlusive crisis. Moreover, the high healthcare spending and increased public awareness about sickle cell diseases are expected to boost the market growth in the region.
Leading Players in the Vaso Occlusive Crisis Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Novartis AG
Headquartered in Basel, Switzerland, Novartis AG is counted among one of the largest pharmaceutical companies in the world. The company actively participates in strategic partnerships with both public and private sectors to advance sickle cell disease care across the globe.
Pfizer Inc.
Pfizer, established in 1849, is one of the leading players in the market. The company is known for its extensive research capabilities and substantial investments in the development of novel therapies. Pfizer is exploring new treatments to address acute pain crises or vaso occlusive crises.
AstraZeneca Plc
This British-Swedish multinational pharmaceutical and biotechnology company has a prominent presence in the market. AstraZeneca boasts a strong portfolio of investigational therapies for various diseases including sickle cell anemia that are in varies stages of clinical development.
Modus Therapeutics Holding AB
Modus Therapeutics, a Swedish biotechnology company, plays a significant role in the growth of the market. The company is involved in testing innovative therapies for diseases with high unmet medical needs including sickle cell disease.
Other key players in the market include Emmaus Life Sciences, Inc., Imara Inc., Sangamo Therapeutics, Inc., bluebird bio, Inc., and NuvOx Pharma LLC.
Key Questions Answered in the Vaso Occlusive Crisis Market Report
Vaso Occlusive Crisis Market Overview
Vaso occlusive crisis is considered the most common clinical manifestation of sickle cell disease. The frequency of crisis is reported to be extremely variable, with some individuals experiencing up to 6 or more episodes in a year. The increasing prevalence of sickle cell disease and the growing patient awareness are expected to augment the market demand for effective treatments. The market is also affected by the rising advancements in gene therapies and increased R&D expenditure by biotechnology and pharmaceutical companies. Moreover, the growth in clinical trial activity and robust regulatory support are some of the factors projected to positively influence the market dynamics in the coming years.
Vaso Occlusive Crisis Market Growth Drivers
Increasing Prevalence of Sickle Cell Disease Drives Market Growth
In the United States, sickle cell disease is reported to affect around 100,000 individuals, comprising over 90% non-Hispanic Black or African American and around 3-9% of Hispanics or Latinos. Further, the disease is highly prevalent in India, particularly among the tribal population. Since vaso occlusive crisis is one of the most common clinical manifestations of sickle cell disease, the rise in the number of such individuals is poised to boost the market growth in the forecast period. Additionally, this rising disease burden is anticipated to propel new drug development efforts for better management of vaso occlusive crisis.
Vaso Occlusive Crisis Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Robust Regulatory Support to Affect the Market Landscape Significantly
In December 2023, two cell-based gene therapies Casgevy and Lyfgenia, developed by Vertex Pharmaceuticals Inc. and Bluebird Bio Inc., respectively, were approved by the U.S. Food and Drug Administration for the treatment of sickle cell disease in patients aged 12 years and above experiencing vaso-occlusive crises. The rise in such approvals by the health authorities is expected to fuel the market growth in the coming years.
Shift Toward Disease-Modifying Therapies Poised to Augment Vaso Occlusive Crisis Market Demand
The market is witnessing a shift towards the development of therapies that target the root cause of sickle cell disease rather than focusing on addressing symptoms that arise during vaso occlusive crisis. Pharmaceutical companies are exploring new therapies that have the ability to alter red blood physiology in order to reduce the frequency of vaso occlusive crisis events and improve overall patient outcomes.
Growth in Clinical Trials to Elevate the Vaso Occlusive Crisis Market Value
Increased clinical trial activity to examine the effectiveness and safety of new treatments for managing vaso occlusive crisis is a major market trend. For instance, Novartis Pharmaceuticals is conducting a Phase II clinical trial to establish and confirm appropriate dosing as well as to examine the safety of its drug crizanlizumab in pediatric patients (aged between 6 months and 18 years) suffering from sickle cell disease with vaso occlusive crisis. The surge in such clinical studies is anticipated to elevate the market value in the forecast period.
Increased Screening Programs to Boost Vaso Occlusive Crisis Market Size
One of the significant market trends is the increase in the number of comprehensive screening programs in high-prevalence regions in order to improve the management of sickle cell anemia and vaso occlusive crisis in the affected patients. National Sickle Cell Anaemia Elimination Mission is one such program launched by the government of India in July 2023, under which 3.37 crore people were screened. Such large-scale screening initiatives are set to augment the market growth in the near future.
Vaso Occlusive Crisis Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type:
- Gene Therapy
- Supportive Care
- Hospital Pharmacies
- Retail Pharmacies
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on Treatment Type is Likely to Witness Substantial Growth
The market breakup by treatment type includes gene therapy and supportive care. The gene therapy segment is poised to dominate the market share owing to the rising advancements in CRISPR technology and other gene editing methods. Further, there is an increase in the number of clinical trials aimed at correcting the defective hemoglobin gene, which is likely to fuel the growth of this segment in the coming years.
Vaso Occlusive Crisis Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States holds a substantial market share which can be attributed to the presence of key market players and the high clinical activity in the region. The market also benefits from the increasing research funding for gene therapies and the growing demand for advanced therapies for vaso occlusive crisis. Moreover, the high healthcare spending and increased public awareness about sickle cell diseases are expected to boost the market growth in the region.
Leading Players in the Vaso Occlusive Crisis Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Novartis AG
Headquartered in Basel, Switzerland, Novartis AG is counted among one of the largest pharmaceutical companies in the world. The company actively participates in strategic partnerships with both public and private sectors to advance sickle cell disease care across the globe.
Pfizer Inc.
Pfizer, established in 1849, is one of the leading players in the market. The company is known for its extensive research capabilities and substantial investments in the development of novel therapies. Pfizer is exploring new treatments to address acute pain crises or vaso occlusive crises.
AstraZeneca Plc
This British-Swedish multinational pharmaceutical and biotechnology company has a prominent presence in the market. AstraZeneca boasts a strong portfolio of investigational therapies for various diseases including sickle cell anemia that are in varies stages of clinical development.
Modus Therapeutics Holding AB
Modus Therapeutics, a Swedish biotechnology company, plays a significant role in the growth of the market. The company is involved in testing innovative therapies for diseases with high unmet medical needs including sickle cell disease.
Other key players in the market include Emmaus Life Sciences, Inc., Imara Inc., Sangamo Therapeutics, Inc., bluebird bio, Inc., and NuvOx Pharma LLC.
Key Questions Answered in the Vaso Occlusive Crisis Market Report
- What was the vaso occlusive crisis market value in 2024?
- What is the vaso occlusive crisis market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on treatment type?
- What is the market breakup based on the distribution channel?
- What are the major factors aiding the vaso occlusive crisis market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of sickle cell anemia affect the market landscape?
- What are the major vaso occlusive crisis market trends?
- How do the rising investments in gene therapies impact the market size?
- Which treatment type will dominate the market share?
- Which distribution channel is expected to have a high market value in the coming years?
- Who are the key players involved in the vaso occlusive crisis market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Vaso Occlusive Crisis Market Overview – 8 Major Markets
- 3.1 Vaso Occlusive Crisis Market Historical Value 2018-2024
- 3.2 Vaso Occlusive Crisis Market Forecast Value 2025-2034
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Vaso Occlusive Crisis Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Vaso Occlusive Crisis Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview 2018-2034
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 EU4
- 7.2.4 India
- 7.2.5 Japan
- 7.3 Diagnosed Cases, by Country
- 7.3.1 United States
- 7.3.2 United Kingdom
- 7.3.3 EU4
- 7.3.4 India
- 7.3.5 Japan
- 7.4 Treatment Seeking Rate, by Country
- 7.4.1 United States
- 7.4.2 United Kingdom
- 7.4.3 EU4
- 7.4.4 India
- 7.4.5 Japan
- 8 Vaso Occlusive Crisis Market Landscape – 8 Major Markets
- 8.1 Vaso Occlusive Crisis Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Vaso Occlusive Crisis Market: Product Landscape
- 8.2.1 Analysis by Treatment Type
- 9 Vaso Occlusive Crisis Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Vaso Occlusive Crisis Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Vaso Occlusive Crisis Market Segmentation 218-2034 - 8 Major Markets
- 12.1 Vaso Occlusive Crisis Market 2018-2034 by Treatment Type
- 12.1.1 Market Overview
- 12.1.2 Gene Therapy
- 12.1.3 Supportive Care
- 12.2 Vaso Occlusive Crisis Market 2018-2034 by Distribution Channel
- 12.2.1 Market Overview
- 12.2.2 Hospital Pharmacies
- 12.2.3 Retail Pharmacies
- 12.2.4 Others
- 12.3 Vaso Occlusive Crisis Market 2018-2034 by Region
- 12.3.1 Market Overview
- 12.3.2 United States
- 12.3.3 EU-4 and the United Kingdom
- 12.3.3.1 Germany
- 12.3.3.2 France
- 12.3.3.3 Italy
- 12.3.3.4 Spain
- 12.3.3.5 United Kingdom
- 12.3.4 Japan
- 12.3.5 India
- 13 United States Vaso Occlusive Crisis Market 218-2034
- 13.1 United States Vaso Occlusive Crisis Market 2018-2034 by Treatment Type
- 13.1.1 Market Overview
- 13.1.2 Gene Therapy
- 13.1.3 Supportive Care
- 13.2 United States Vaso Occlusive Crisis Market 2018-2034 by Distribution Channel
- 13.2.1 Market Overview
- 13.2.2 Hospital Pharmacies
- 13.2.3 Retail Pharmacies
- 13.2.4 Others
- 14 EU-4 and United Kingdom Vaso Occlusive Crisis Market 218-2034
- 14.1 EU-4 and United Kingdom Vaso Occlusive Crisis Market 2018-2034 by Treatment Type
- 14.1.1 Market Overview
- 14.1.2 Gene Therapy
- 14.1.3 Supportive Care
- 14.2 EU-4 and United Kingdom Vaso Occlusive Crisis Market 2018-2034 by Distribution Channel
- 14.2.1 Market Overview
- 14.2.2 Hospital Pharmacies
- 14.2.3 Retail Pharmacies
- 14.2.4 Others
- 15 Japan Vaso Occlusive Crisis Market 218-2034
- 15.1 Japan Vaso Occlusive Crisis Market 2018-2034 by Treatment Type
- 15.1.1 Market Overview
- 15.1.2 Gene Therapy
- 15.1.3 Supportive Care
- 15.2 Japan Vaso Occlusive Crisis Market 2018-2034 by Distribution Channel
- 15.2.1 Market Overview
- 15.2.2 Hospital Pharmacies
- 15.2.3 Retail Pharmacies
- 15.2.4 Others
- 16 India Vaso Occlusive Crisis Market 218-2034
- 16.1 India Vaso Occlusive Crisis Market 2018-2034 by Treatment Type
- 16.1.1 Market Overview
- 16.1.2 Gene Therapy
- 16.1.3 Supportive Care
- 16.2 India Vaso Occlusive Crisis Market 2018-2034 by Distribution Channel
- 16.2.1 Market Overview
- 16.2.2 Hospital Pharmacies
- 16.2.3 Retail Pharmacies
- 16.2.4 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Class of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Drug Class of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 Novartis AG
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Developments
- 23.2.5 Certifications
- 23.3 Pfizer Inc.
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Developments
- 23.3.5 Certifications
- 23.4 AstraZeneca Plc
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Developments
- 23.4.5 Certifications
- 23.5 Modus Therapeutics Holding AB
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Developments
- 23.5.5 Certifications
- 23.6 Emmaus Life Sciences, Inc.
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Developments
- 23.6.5 Certifications
- 23.7 Imara Inc.
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Developments
- 23.7.5 Certifications
- 23.8 NuvOx Pharma LLC
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Developments
- 23.8.5 Certifications
- 23.9 Sangamo Therapeutics, Inc.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Developments
- 23.9.5 Certifications
- 23.10 bluebird bio, Inc.
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Developments
- 23.10.5 Certifications
- 24 Vaso Occlusive Crisis Market - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
